HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with
overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability
of HTI-1066 in subjects with advanced solid tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT03398720.
See trial information on ClinicalTrials.gov for a list of participating sites.
This is a 2-part dose escalation and dose expansion study. Dose escalation uses a
modified "3+3" design and continues until a maximum tolerated dose (MTD) or recommended
phase 2 dose (RP2D) is identified. In part 2, subjects with selected tumor types will be
enrolled at the MTD or RP2D.
Lead OrganizationJiangsu HengRui Medicine Co., Ltd.